StockData
Avalyn Pharma Inc. logo

Avalyn Pharma Inc. (AVLN) stock

AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.92−1.84 (-6.18%)

Close on Nov 17, 2026Market cap $1.24BP/E –Yield –

Avalyn Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$24.73M–
Q1 FY2026Mar 31, 2026$22.89M–
Q2 FY2025Jun 30, 2025$17.88M–
Q1 FY2025Mar 31, 2025$15.32M–

More Avalyn Pharma figures

See a number that looks wrong?